Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Shuai Xia(Shanghai Medical College of Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Qiaoshuai Lan(Chinese University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Linlin Bao(Chinese Academy of Medical Sciences & Peking Union Medical College), Chuan Qin(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Zhu(Chinese Academy of Sciences), Shuwen Liu(Zhengzhou University), Fei Sun(University of California, Los Angeles), Chao Wang, Feifei Qi(Chinese Academy of Sciences), Siliang Feng, Wei Xu(Beijing Geriatric Hospital), Meiqin Liu, Lanying Du(Georgia State University)
Cited by 14
Related Papers
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
|Nature Medicine|2005|3.7k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
From SARS to MERS, Thrusting Coronaviruses into the Spotlight
|Viruses|2019|1.3k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k